Cefamandole nafate
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Cefamandole nafate is a second generation cephalosporin indicated in the prevention of infections during surgery.
- Generic Name
- Cefamandole nafate
- DrugBank Accession Number
- DB14725
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Cefamandole nafate (DB14725)
- Weight
- Average: 490.51
Monoisotopic: 490.072924672 - Chemical Formula
- C19H18N6O6S2
- Synonyms
- O-formylcefamandole
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefamandole nafate. Acenocoumarol The risk or severity of bleeding can be increased when Cefamandole nafate is combined with Acenocoumarol. Alteplase The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefamandole nafate. Ancrod The therapeutic efficacy of Ancrod can be decreased when used in combination with Cefamandole nafate. Anistreplase The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefamandole nafate. Antithrombin Alfa The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefamandole nafate. Antithrombin III human The therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Cefamandole nafate. Apixaban The therapeutic efficacy of Apixaban can be decreased when used in combination with Cefamandole nafate. Ardeparin The therapeutic efficacy of Ardeparin can be decreased when used in combination with Cefamandole nafate. Argatroban The therapeutic efficacy of Argatroban can be decreased when used in combination with Cefamandole nafate. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Cefamandole nafate sodium 8HDO7941DO 42540-40-9 ICZOIXFFVKYXOM-YCLOEFEOSA-M - Active Moieties
Name Kind UNII CAS InChI Key Cefamandole prodrug 5CKP8C2LLI 34444-01-4 OLVCFLKTBJRLHI-AXAPSJFSSA-N - International/Other Brands
- Kefadol (Lilly) / Kefandol (Lilly) / Mandokef (Lilly) / Mandol (Lilly)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Mandol Inj 1gm/amp Powder, for solution 1 g / amp Intramuscular; Intravenous Eli Lilly & Co. Ltd. 1978-12-31 2000-10-02 Canada 
Mandol Inj 2gm/amp Powder, for solution 2 g / amp Intravenous Eli Lilly & Co. Ltd. 1978-12-31 2000-08-03 Canada
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 57268-80-1
- InChI Key
- RRJHESVQVSRQEX-SUYBPPKGSA-N
- InChI
- InChI=1S/C19H18N6O6S2/c1-24-19(21-22-23-24)33-8-11-7-32-17-12(16(28)25(17)13(11)18(29)30)20-15(27)14(31-9-26)10-5-3-2-4-6-10/h2-6,9,12,14,17H,7-8H2,1H3,(H,20,27)(H,29,30)/t12-,14-,17-/m1/s1
- IUPAC Name
- (6R,7R)-7-[(2R)-2-(formyloxy)-2-phenylacetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- SMILES
- [H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](OC=O)C1=CC=CC=C1)C(O)=O
References
- General References
- BPOM Product Information: Cefamandole nafate injection [Link]
- External Links
- ChemSpider
- 4447585
- 20473
- ChEBI
- 53654
- ChEMBL
- CHEMBL1201218
- ZINC
- ZINC000003830397
- Wikipedia
- Cefamandole
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 0 Terminated Treatment Osteomyelitis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Parenteral 1 G Injection, powder, for solution Parenteral Powder, for solution Intramuscular; Intravenous 1 g / amp Powder, for solution Intravenous 2 g / amp - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.227 mg/mL ALOGPS logP 0.61 ALOGPS logP 0.42 ChemAxon logS -3.3 ALOGPS pKa (Strongest Acidic) 3.1 ChemAxon pKa (Strongest Basic) -1.7 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 8 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 156.61 Å2 ChemAxon Rotatable Bond Count 9 ChemAxon Refractivity 131.31 m3·mol-1 ChemAxon Polarizability 45.27 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on December 14, 2018 17:21 / Updated on August 17, 2021 04:17